Exelixis (EXEL) EPS (Weighted Average and Diluted) (2010 - 2026)
Exelixis (EXEL) recorded quarterly EPS (Weighted Average and Diluted) of $0.79 in Q2 2026, down 10.23% quarter-over-quarter from $0.88 in Q1 2026, and up 43.64% on a YoY basis from $0.55 in Q2 2025.
Exelixis (EXEL) EPS (Weighted Average and Diluted) (2010 - 2026) Analysis & Trends
Exelixis' EPS (Weighted Average and Diluted) history runs 15 years deep, the most recent figure standing at $0.79 for Q2 2026.
- In Q2 2026, EPS (Weighted Average and Diluted) rose 43.64% year-over-year to $0.79; the TTM figure through Apr 2026 stood at $3.01 (up 36.82% YoY), while the FY2026 annual figure was $2.78, up 57.95% from the prior year.
- EPS (Weighted Average and Diluted) was $0.79 for Q2 2026 at Exelixis, down from $0.88 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.88 in Q1 2026 to a low of -$0.09 in Q4 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged $0.38 across 5 years, with a median of $0.27 in 2023.
- The sharpest annual moves came in 2022 and 2024: EPS (Weighted Average and Diluted) sank 130.49% in 2022, then soared 12360.21% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.09 in 2022, then soared by 400.0% to $0.27 in 2023, then surged by 48.15% to $0.4 in 2024, then jumped by 72.5% to $0.69 in 2025, then grew by 14.49% to $0.79 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.79 (Q2 2026), $0.88 (Q1 2026), and $0.69 (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 0.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -0.61 |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn | 0.79 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 0.79 |
| Jan 2, 2026 | 0.88 |
| Oct 3, 2025 | 0.69 |
| Jul 4, 2025 | 0.65 |
| Apr 4, 2025 | 0.55 |
| Jan 3, 2025 | 0.48 |
| Sep 27, 2024 | 0.40 |
| Jun 28, 2024 | 0.77 |
| Mar 29, 2024 | 0.12 |
| Dec 29, 2023 | 0.27 |
| Sep 29, 2023 | 0.00 |
| Jun 30, 2023 | 0.25 |
| Mar 31, 2023 | 0.12 |
| Dec 30, 2022 | -0.09 |
| Sep 30, 2022 | 0.23 |
| Jul 1, 2022 | 0.22 |
| Apr 1, 2022 | 0.21 |
| Dec 31, 2021 | 0.30 |
| Oct 1, 2021 | 0.12 |
| Jul 2, 2021 | 0.30 |